Labcorp Drug Development - Company Profile
Powered by 
All the data and insights you need on Labcorp Drug Development in one report.
$295
- Save hours of research time and resources with
our up-to-date Labcorp Drug Development Strategy Report
- Understand Labcorp Drug Development position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Labcorp Drug Development (Labcorp), formerly known as Covance Inc, is a contract research company that offers drug development and manufacturing services. Its services include research, lead optimization, analysis services, safety assessment and drug safety testing, consulting and partnering, informatics, clinical testing, clinical development, commercialization, and manufacturing support, among others. It offers solutions in various therapeutic areas such as cardiovascular; diabetes, endocrinology and nephrology; immuno-oncology; infectious diseases; inflammation; neuroscience; non-alcoholic steatohepatitis; oncology; rare disease and orphan drugs; and pediatrics. Labcorp also offers laboratory testing services for agrochemical and chemical industries. It operates in the US, Europe, Latin America, Africa, and Asia-Pacific. The company operates as a subsidiary of Laboratory Corp of America Holdings. Labcorp is headquartered in Burlington, North Carolina, the US.
Headquarters
United States of America
Address
531 S. Spring Road, Burlington, North Carolina, 46214
Website
www.drugdevelopment.labcorp.com
Telephone
1 336 5845171
Industry
Pharmaceuticals and Healthcare
Labcorp Drug Development premium industry data and analytics
Products and Services
| Services | Brands |
|---|---|
| Research | FSPx |
| Lead Optimization | TeleCenter |
| Analysis Services | LabLink |
| XYZ | XYZ |
| XYZ | XYZ |
| XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2023 | Contracts/Agreements | In March, the company entered into an agreement to acquire the assets of Enzo Biochem, Inc.'s Clinical Laboratory division. |
| 2022 | Contracts/Agreements | In July, the company entered into a collaboration with Redi.Health for helping patients better manage their health. |
| 2021 | Contracts/Agreements | In September, the company along with the Biomedical Advanced Research and Development Authority entered into a collaboration with Partner Therapeutics, Inc. to advance a new diagnostic approach to select immunoparalyzed sepsis patients. |
Competitor Comparison
| Key Parameters | Labcorp Drug Development | IQVIA Holdings Inc | ICON Plc | Charles River Laboratories International Inc | Frontage Holdings Corp |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | Ireland | United States of America | United States of America |
| City | Burlington | Durham | Dublin | Wilmington | Exton |
| State/Province | North Carolina | North Carolina | Dublin | Massachusetts | Pennsylvania |
| No. of Employees | - | 87,000 | 41,100 | 20,000 | 1,613 |
| Entity Type | Private | Public | Public | Public | Public |
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Steven Anderson, Ph.D. | Chief Scientific Officer | Senior Management | 2016 | - |
| Adam H. Schechter | President; Chief Executive Officer | Senior Management | - | - |
| Judi Seltz | Chief Human Resources Officer | Senior Management | 2022 | - |
| Honggang Bi, Ph.D. | Head - Asia Pacific Region; Senior Vice President | Senior Management | - | - |
| Paul Kirchgraber, M.D. | Chief Executive Officer - Covance | Senior Management | 2020 | - |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer